CY1122156T1 - Αντισωματα κατα του σχετιζομενου με τον νεφρο αντιγονου 1 και αντιγονοδεσμευτικα θραυσματα αυτων - Google Patents
Αντισωματα κατα του σχετιζομενου με τον νεφρο αντιγονου 1 και αντιγονοδεσμευτικα θραυσματα αυτωνInfo
- Publication number
- CY1122156T1 CY1122156T1 CY20191100961T CY191100961T CY1122156T1 CY 1122156 T1 CY1122156 T1 CY 1122156T1 CY 20191100961 T CY20191100961 T CY 20191100961T CY 191100961 T CY191100961 T CY 191100961T CY 1122156 T1 CY1122156 T1 CY 1122156T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cancer
- antigen
- antibodies
- binding fragments
- kidney
- Prior art date
Links
- 239000012634 fragment Substances 0.000 title abstract 4
- 102100040442 Kidney-associated antigen 1 Human genes 0.000 title abstract 3
- 101710197393 Kidney-associated antigen 1 Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 3
- 101000614481 Homo sapiens Kidney-associated antigen 1 Proteins 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 238000001514 detection method Methods 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 208000003174 Brain Neoplasms Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 208000008839 Kidney Neoplasms Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 206010038389 Renal cancer Diseases 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000010982 kidney cancer Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from kidney or bladder cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3038—Kidney, bladder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Abstract
Νέα αντισώματα και αντιγονοδεσμευτικά θραύσματα που δεσμεύονται ειδικά στο KAAG1 και που μπορεί να χρησιμοποιηθούν στην αγωγή, την ανίχνευση και τη διάγνωση του καρκίνου που περιλαμβάνει κύτταρα που εκφράζουν KAAG1 αποκαλύπτονται στο παρόν. Τα κύτταρα που εκφράζουν τα αντισώματα και τα αντιγονοδεσμευτικά θραύσματα καθώς επίσης και μέθοδοι ανιχνεύσεως και αγωγής του καρκίνου δια της χρήσεως των αντισωμάτων και θραυσμάτων αποκαλύπτονται επίσης. Οι ενδείξεις του καρκίνου που μπορεί να ωφεληθούν από αυτήν την αγωγή ή την ανίχνευση περιλαμβάνουν καρκίνο των ωοθηκών, νεφρικό καρκίνο, καρκίνο του πνεύμονα, ορθοκολικό καρκίνο, καρκίνο του μαστού, καρκίνο του εγκεφάλου και καρκίνο του προστάτη καθώς επίσης και μελανώματα.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161470063P | 2011-03-31 | 2011-03-31 | |
US201161533346P | 2011-09-12 | 2011-09-12 | |
PCT/CA2012/000296 WO2012129668A1 (en) | 2011-03-31 | 2012-03-28 | Antibodies against kidney associated antigen 1 and antigen binding fragments thereof |
EP12765926.6A EP2691421B1 (en) | 2011-03-31 | 2012-03-28 | Antibodies against kidney associated antigen 1 and antigen binding fragments thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1122156T1 true CY1122156T1 (el) | 2020-11-25 |
Family
ID=46929256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20191100961T CY1122156T1 (el) | 2011-03-31 | 2019-09-16 | Αντισωματα κατα του σχετιζομενου με τον νεφρο αντιγονου 1 και αντιγονοδεσμευτικα θραυσματα αυτων |
Country Status (23)
Country | Link |
---|---|
US (5) | US8937163B2 (el) |
EP (3) | EP3173427B1 (el) |
JP (3) | JP6294221B2 (el) |
KR (2) | KR101993259B1 (el) |
CN (2) | CN106146664B (el) |
AU (1) | AU2012234754B2 (el) |
BR (1) | BR112013025198A2 (el) |
CA (3) | CA2829105C (el) |
CY (1) | CY1122156T1 (el) |
DK (2) | DK3173427T3 (el) |
EA (1) | EA038979B1 (el) |
ES (2) | ES2743913T3 (el) |
HR (1) | HRP20191590T1 (el) |
HU (1) | HUE045943T2 (el) |
IL (3) | IL228434B (el) |
LT (1) | LT3173427T (el) |
MX (1) | MX352373B (el) |
PL (1) | PL3173427T3 (el) |
PT (1) | PT3173427T (el) |
RS (1) | RS59080B1 (el) |
SI (1) | SI3173427T1 (el) |
WO (1) | WO2012129668A1 (el) |
ZA (1) | ZA201307027B (el) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110084280A (ko) | 2008-11-03 | 2011-07-21 | 알레시아 바이오쎄라퓨틱스 인코포레이티드 | 종양 항원의 생물 활성을 특이적으로 차단하는 항체 |
CA2829105C (en) * | 2011-03-31 | 2019-09-24 | Alethia Biotherapeutics Inc. | Antibodies against kidney associated antigen 1 and antigen binding fragments thereof |
PL2802351T3 (pl) | 2012-01-09 | 2019-11-29 | Adc Therapeutics Sa | Środki do leczenia potrójnie negatywnego raka piersi |
US20130280282A1 (en) * | 2012-04-24 | 2013-10-24 | Daiichi Sankyo Co., Ltd. | Dr5 ligand drug conjugates |
EP3939616A1 (en) | 2017-02-08 | 2022-01-19 | ADC Therapeutics SA | Pyrrolobenzodiazepine-antibody conjugates |
IL266153A (en) * | 2019-04-18 | 2019-07-31 | Aharon Anat | Extracellular vesicles derived from t cells containing a chimeric antigen receptor |
GB201908128D0 (en) | 2019-06-07 | 2019-07-24 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
WO2024036333A2 (en) | 2022-08-12 | 2024-02-15 | Epibiologics, Inc. | Degradation of egfr using a bispecific binding agent |
Family Cites Families (195)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US662392A (en) | 1899-12-12 | 1900-11-27 | Friedrich Wilhelm Buehne | Method of making metal wool. |
US5075447A (en) | 1984-09-17 | 1991-12-24 | Hoffmann-La Roche Inc. | Ruthenium complexes useful as carriers for immunologically active materials |
DK365785A (da) | 1984-09-17 | 1986-03-18 | Hoffmann La Roche | Metalcomplexer |
GB8601646D0 (en) | 1986-01-23 | 1986-02-26 | Davidson R S | Binding assay & reagent |
US5585279A (en) | 1986-01-23 | 1996-12-17 | Davidson; Robert S. | Time-resolved luminescence binding assays using a fluorescent transition metal label other than ruthenium |
US6018030A (en) | 1986-11-04 | 2000-01-25 | Protein Polymer Technologies, Inc. | Peptides comprising repetitive units of amino acids and DNA sequences encoding the same |
HUT61296A (en) | 1989-12-28 | 1992-12-28 | Upjohn Co | Process for producing substituted diaromatic compounds against aids and pharmaceutical compositions comprising same |
IL105325A (en) | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
WO1996013510A1 (en) | 1994-10-28 | 1996-05-09 | Procept, Inc. | Ruthenium complexes and their use as immunosuppressive agents |
US5708022A (en) | 1994-10-28 | 1998-01-13 | Procept, Inc. | Method for inhibiting immune response |
US5712127A (en) | 1996-04-29 | 1998-01-27 | Genescape Inc. | Subtractive amplification |
US5831003A (en) | 1996-06-28 | 1998-11-03 | Bayer Corporation | Peptides which bind to prothrombin and thrombin |
US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
EP0991777A1 (en) | 1997-06-18 | 2000-04-12 | Ulrich J. Krull | Nucleic acid biosensor diagnostics |
AU1824899A (en) | 1997-12-15 | 1999-07-05 | Joseph R Lakowicz | Method and composition for characterizing a sample containing a sample lipid andan assay kit |
US6759243B2 (en) | 1998-01-20 | 2004-07-06 | Board Of Trustees Of The University Of Illinois | High affinity TCR proteins and methods |
US6472367B1 (en) | 1998-05-05 | 2002-10-29 | Adherex Technologies, Inc. | Compounds and methods for modulating OB-cadherin mediated cell adhesion |
WO1999058655A2 (en) | 1998-05-13 | 1999-11-18 | Diversys Limited | Phage display selection system for folded proteins |
EP1077989A4 (en) | 1998-05-13 | 2002-01-02 | Ludwig Inst Cancer Res | ANTIGEN WITH TUMOR ASSOCIATION ENCODED BY THE ANTISENSE STRAND OF A NEW GENE WITH UBIQUISTIC EXPRESSION |
US7037667B1 (en) | 1998-06-01 | 2006-05-02 | Agensys, Inc. | Tumor antigen useful in diagnosis and therapy of prostate and colon cancer |
US7521197B2 (en) | 1998-06-05 | 2009-04-21 | Alexis Biotech Limited | Method for producing cytotoxic T-cells |
US20020106678A1 (en) | 1998-06-30 | 2002-08-08 | Robishaw Janet D. | cDNA clones encoding human G protein gamma subunits |
EP1090012A4 (en) | 1998-07-02 | 2005-04-06 | Merck & Co Inc | INHIBITORS OF PRENYL PROTEIN TRANSFERASE |
US6288221B1 (en) | 1998-08-20 | 2001-09-11 | Duke University | Methods of synthesis of halogen base-modified oligonucleotides and subsequent labeling with a metal-catalyzed reaction |
US6806089B1 (en) | 1998-09-08 | 2004-10-19 | University Of Maryland, Baltimore | Low frequency modulation sensors using nanosecond fluorophores |
WO2000014515A1 (en) | 1998-09-08 | 2000-03-16 | University Of Maryland At Baltimore | Low frequency modulation sensors using nanosecond fluorophores |
AU1223400A (en) | 1998-10-22 | 2000-05-08 | Phillip B. B. Moheno | Novel pterin antineoplastic agents |
WO2000025788A1 (en) | 1998-10-29 | 2000-05-11 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
US20020049190A1 (en) | 1999-03-19 | 2002-04-25 | Bridger Gary J. | Pharmaceutical compositions comprising metal complexes |
US6872519B1 (en) | 1999-04-27 | 2005-03-29 | Mirus Bio Corporation | In vitro process for selecting phage resistant to blood inactivation |
US20090087878A9 (en) | 1999-05-06 | 2009-04-02 | La Rosa Thomas J | Nucleic acid molecules associated with plants |
GB9916529D0 (en) | 1999-07-14 | 1999-09-15 | Chiron Spa | Antigenic peptides |
BR0014078A (pt) | 1999-09-17 | 2002-12-31 | Millennium Pharm Inc | Inibidores de fator xa |
WO2001046209A1 (en) | 1999-12-20 | 2001-06-28 | Fluorrx, Inc. | Fluorescent probes |
US20030219806A1 (en) | 2000-02-22 | 2003-11-27 | Millennium Pharmaceuticals, Inc. | Novel 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 molecules and uses therefor |
US7585839B2 (en) | 2000-02-23 | 2009-09-08 | Zealand Pharma A/S | Medical uses of intercellular communication facilitating compounds |
US20030215860A1 (en) | 2000-02-29 | 2003-11-20 | Millennium Pharmaceuticals, Inc. | Novel 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 molecules and uses therefor |
WO2001070979A2 (en) | 2000-03-21 | 2001-09-27 | Millennium Pharmaceuticals, Inc. | Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer |
US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
US7834146B2 (en) | 2000-05-08 | 2010-11-16 | Monsanto Technology Llc | Recombinant polypeptides associated with plants |
AU2001269836A1 (en) | 2000-06-16 | 2002-01-02 | Incyte Genomics, Inc. | Proteases |
AU2002214531A1 (en) | 2000-07-03 | 2002-01-30 | Curagen Corporation | Proteins and nucleic acids encoding same |
US20050053930A1 (en) | 2000-07-18 | 2005-03-10 | David Anderson | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
US6812339B1 (en) | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
GB0023008D0 (en) | 2000-09-20 | 2000-11-01 | Glaxo Group Ltd | Improvements in vaccination |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7320793B2 (en) | 2001-01-19 | 2008-01-22 | Cytos Biotechnology Ag | Molecular antigen array |
TWI329129B (en) | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
US6783969B1 (en) | 2001-03-05 | 2004-08-31 | Nuvelo, Inc. | Cathepsin V-like polypeptides |
US7030236B2 (en) | 2001-03-09 | 2006-04-18 | Mona Savitri Jhaveri | Antisense oligonucleotides tarageting folate receptor alpha, and the use thereof |
AU2002258518A1 (en) | 2001-03-14 | 2002-09-24 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer |
US20030065157A1 (en) | 2001-04-04 | 2003-04-03 | Lasek Amy W. | Genes expressed in lung cancer |
WO2002083921A2 (en) | 2001-04-10 | 2002-10-24 | Agensys, Inc. | Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers |
WO2002086443A2 (en) | 2001-04-18 | 2002-10-31 | Protein Design Labs, Inc | Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer |
WO2002090533A2 (en) | 2001-05-07 | 2002-11-14 | National Research Council Of Canada | Enhanced production of recombinant proteins by transient transfection of suspension-growing mammalian cells |
US20100056762A1 (en) * | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
EP1517998A2 (en) | 2001-06-18 | 2005-03-30 | EOS Biotechnology, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
US20040053824A1 (en) | 2001-06-29 | 2004-03-18 | Tang Y Tom | Extracellular matrix and cell adhesion molecules |
US20030099974A1 (en) | 2001-07-18 | 2003-05-29 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer |
PT1421105E (pt) | 2001-08-31 | 2010-12-07 | Btg Int Ltd | Compostos anticancerígenos de ciclopenta-g quinazolina |
WO2003020300A1 (en) | 2001-08-31 | 2003-03-13 | Btg International Limited | Use of cyclopenta[g]quinazoline derivatives for treating cancer |
US20030124579A1 (en) | 2001-09-05 | 2003-07-03 | Eos Biotechnology, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
US7622260B2 (en) | 2001-09-05 | 2009-11-24 | The Brigham And Women's Hospital, Inc. | Diagnostic and prognostic tests |
AR045702A1 (es) | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
US7338965B2 (en) | 2001-11-19 | 2008-03-04 | Pharmacia & Upjohn Company | 3,4-disubstituted, 3,5-disubstituted and 3,4,5-substituted piperidines |
WO2003047526A2 (en) | 2001-11-30 | 2003-06-12 | Incyte Genomics, Inc. | Cell adhesion and extracellular matrix proteins |
DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
AU2003201733B2 (en) | 2002-01-09 | 2008-11-06 | Xigen Sa | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
US8048408B2 (en) | 2002-01-16 | 2011-11-01 | Biocompatibles Uk Limited | Polymer conjugates |
JP2005516072A (ja) | 2002-01-28 | 2005-06-02 | ケラプラスト テクノロジーズ, リミテッド | 生物活性ケラチンタンパク質 |
US6962910B2 (en) | 2002-02-01 | 2005-11-08 | Virginia Tech Intellectual Properties, Inc. | Supramolecular complexes as photoactivated DNA cleavage agents |
AU2003225573A1 (en) | 2002-02-13 | 2003-09-04 | The Government Of The United States Of America As Represented By The Secretary, Department Of He | Identification of ovarian cancer tumor markers and therapeutic targets |
DE10206616A1 (de) | 2002-02-15 | 2003-09-04 | Qiagen Gmbh | Verfahren zur Reduktion der Background-Kontamination nach Markierungsreaktionen |
US20040009939A1 (en) | 2002-03-05 | 2004-01-15 | Board Of Regent, The University Of Texas System | Methods of enhancing immune induction involving MDA-7 |
CN1305905C (zh) | 2002-03-22 | 2007-03-21 | Aprogen株式会社 | 人源化抗体及其制备方法 |
WO2003087768A2 (en) | 2002-04-12 | 2003-10-23 | Mitokor | Targets for therapeutic intervention identified in the mitochondrial proteome |
US20040033543A1 (en) | 2002-05-20 | 2004-02-19 | Gisela Schwab | Treatment of renal carcinoma using antibodies against the EGFr |
WO2004030615A2 (en) | 2002-10-02 | 2004-04-15 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
EP1422242A1 (en) | 2002-11-22 | 2004-05-26 | Emory University | Plastic and elastic protein copolymers |
JP2006519008A (ja) | 2003-02-10 | 2006-08-24 | 独立行政法人産業技術総合研究所 | 哺乳動物細胞の調節 |
WO2004087874A2 (en) | 2003-03-28 | 2004-10-14 | Nuvelo, Inc. | Novel nucleic acids and polypeptides |
EP1635866A2 (en) | 2003-05-20 | 2006-03-22 | Cellpep S.A. | Modified antiviral peptides with increased activity and cell membrane affinity |
WO2004104197A1 (en) | 2003-05-21 | 2004-12-02 | Genesense Technologies Inc. | Antisense oligonucleotides directed to ribonucleotide reductase r1 and uses thereof in the treatment of cancer |
US20050008649A1 (en) | 2003-06-02 | 2005-01-13 | University Of Miami | Chimeric molecules and methods of use |
WO2005004795A2 (en) | 2003-06-09 | 2005-01-20 | University Of Cincinnati | Compositions and methods for targeted drug delivery |
US20060078941A1 (en) | 2003-06-09 | 2006-04-13 | Santin Alessandro D | Gene expression profiling in primary ovarian serous papillary tumors and normal ovarian epithelium |
GB0314472D0 (en) | 2003-06-20 | 2003-07-23 | Warwick Effect Polymers Ltd | Polymer |
GB0318096D0 (en) | 2003-08-01 | 2003-09-03 | Queen Mary & Westfield College | Vaccine |
DE10335833A1 (de) | 2003-08-05 | 2005-03-03 | Curevac Gmbh | Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie |
US20070178458A1 (en) | 2003-09-05 | 2007-08-02 | O'brien Philippa | Methods of diagnosis and prognosis of ovarian cancer II |
US20050147621A1 (en) | 2003-10-10 | 2005-07-07 | Higgins Darren E. | Use of bacterial 5' untranslated regions for nucleic acid expression |
DE10347710B4 (de) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
US7202234B2 (en) | 2003-10-24 | 2007-04-10 | Eisai Co., Ltd. | Compounds and methods for treating Toll-like receptor 2-related diseases and conditions |
US20050153333A1 (en) | 2003-12-02 | 2005-07-14 | Sooknanan Roy R. | Selective terminal tagging of nucleic acids |
EP1547581A1 (en) | 2003-12-23 | 2005-06-29 | Vectron Therapeutics AG | Liposomal vaccine for the treatment of human hematological malignancies |
EP1550458A1 (en) | 2003-12-23 | 2005-07-06 | Vectron Therapeutics AG | Synergistic liposomal adjuvants |
US20050202020A1 (en) | 2004-01-09 | 2005-09-15 | Jeffrey Ross | Diagnosing and treating cancer |
CA2551064A1 (en) | 2004-01-09 | 2005-07-21 | Yissum Research Development Company Of The Hebrew University Of Jerusale M | Compounds, pharmaceutical compositions and therapeutic methods of preventing and treating diseases and disorders associated with amyloid fibril formation |
EP1747284A4 (en) | 2004-02-06 | 2009-03-11 | Wyeth Corp | DIAGNOSTICS AND THERAPEUTICS OF CANCER |
JP4912894B2 (ja) | 2004-02-19 | 2012-04-11 | イェール ユニバーシティー | プロテオーム技術を使用した癌タンパク質バイオマーカーの同定 |
AU2005215943A1 (en) | 2004-03-01 | 2005-09-09 | Peptera Pharmaceutical Ltd. | Casein derived peptides and therapeutic uses thereof |
JP5017107B2 (ja) | 2004-07-06 | 2012-09-05 | ワーウィック イフェクト ポリマーズ リミテッド | ポリペプチド等と反応し得る官能基を含むリビングラジカル重合開始剤、それを用いて得られる櫛形ポリマー、それから得られるポリペプチド複合体及び薬剤 |
WO2007084413A2 (en) | 2004-07-14 | 2007-07-26 | Ptc Therapeutics, Inc. | Methods for treating hepatitis c |
US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US7553944B2 (en) | 2004-07-21 | 2009-06-30 | The University Of Hong Kong | Human virus causing respiratory tract infection and uses thereof |
US20080280317A1 (en) | 2004-08-27 | 2008-11-13 | Northeastern University | Comprehensive Characterization Of Complex Proteins At Trace Levels |
DE102004042546A1 (de) | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
WO2006027202A1 (en) | 2004-09-06 | 2006-03-16 | Unite De Recherche En Biotherapie Et Oncologie (Rubio) | Generation of multiparent cell hybrids |
US7829708B2 (en) | 2004-09-08 | 2010-11-09 | Chelsea Therapeutics, Inc. | Metabolically inert antifolates for treating disorders of abnormal cellular proliferation and inflammation |
US8247371B2 (en) | 2004-10-14 | 2012-08-21 | Yale University | Therapy with Clostridium perfringens enterotoxin to treat ovarian and uterine cancer |
WO2006050247A2 (en) | 2004-10-29 | 2006-05-11 | Neose Technologies, Inc. | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
AU2005323062A1 (en) | 2005-01-04 | 2006-07-13 | The Brigham And Women's Hospital, Inc. | Sustained delivery of PDGF using self-assembling peptide nanofibers |
CN101133037B (zh) | 2005-01-27 | 2012-05-09 | 旭化成制药株式会社 | 六元杂环化合物及其用途 |
US7531533B2 (en) | 2005-01-27 | 2009-05-12 | Asahi Kasei Pharma Corporation | 6-Membered heterocyclic compound and use thereof |
NZ613923A (en) | 2005-02-14 | 2015-02-27 | Epitopix Llc | Antibody compositions that bind polypeptides from staphylococcus aureus |
JP2008532014A (ja) | 2005-02-24 | 2008-08-14 | セマインズ,インコーポレイティド | 生物試料を分類するための組成物及び方法 |
JP2008537544A (ja) | 2005-03-17 | 2008-09-18 | プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ | アブラインビルアミド、ステファシジンbおよびそれらのアナログの合成 |
CA2578908C (en) | 2005-03-17 | 2020-05-26 | Yves Durocher | Expression vectors for enhanced transient gene expression and mammalian cells expressing them |
FR2885525B1 (fr) | 2005-05-13 | 2009-09-18 | Urodelia Sa | Medicament notamment anti-cancereux, destine a des traitements par immunotherapie, en particulier autologue |
KR101604799B1 (ko) | 2005-06-13 | 2016-03-28 | 클리브랜드 바이오랩스, 아이엔씨. | 리포펩티드를 사용하여 아폽토시스에 대항하는 보호방법 |
AU2006259415B2 (en) | 2005-06-15 | 2012-08-30 | Massachusetts Institute Of Technology | Amine-containing lipids and uses thereof |
WO2007002563A1 (en) | 2005-06-27 | 2007-01-04 | Exelixis, Inc. | Imidazole based lxr modulators |
WO2007005249A2 (en) | 2005-06-29 | 2007-01-11 | Hyperbranch Medical Technology, Inc. | Nanoparticles and dendritic-polymer-based hydrogels comprising them |
US7494788B2 (en) | 2005-07-11 | 2009-02-24 | Molecular Kinetics, Inc. | Entropic bristle domain sequences and their use in recombinant protein production |
US7820790B2 (en) | 2005-07-13 | 2010-10-26 | Amgen Mountain View Inc. | IL-6 binding proteins |
US20090005268A1 (en) | 2005-07-18 | 2009-01-01 | Epigenomics Ag | Compositions and Methods for Cancer Diagnostics Comprising Pan-Cancer Markers |
GB0516058D0 (en) | 2005-08-04 | 2005-09-14 | Oxford Genome Sciences Uk Ltd | New protein isoforms and uses thereof |
GB0517293D0 (en) | 2005-08-24 | 2005-10-05 | Cancer Rec Tech Ltd | Vectors and uses thereof |
WO2007031080A1 (en) | 2005-09-15 | 2007-03-22 | Alk-Abelló A/S | A method for quantification of allergens |
WO2007044885A2 (en) | 2005-10-11 | 2007-04-19 | Chemocentryx, Inc. | Piperidine derivatives and methods of use |
WO2007045876A1 (en) | 2005-10-21 | 2007-04-26 | Merz Pharma Gmbh & Co. Kgaa | Chromenones and their use as modulators of metabotropic glutamate receptors |
UA96139C2 (uk) | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Антитіло до нейропіліну-1 (nrp1) |
ATE486875T1 (de) | 2005-11-10 | 2010-11-15 | Chemocentryx Inc | Substituierte chinolone und verwendungsverfahren |
WO2007061853A2 (en) | 2005-11-23 | 2007-05-31 | Merck & Co., Inc. | Process for synthesizing 2-phenyl-1h-phenantrho[9,10-d]imidazole derivative |
KR101049859B1 (ko) | 2007-11-28 | 2011-07-19 | 대한민국 | N-말단 pI 값 조절에 의한 수용성 재조합 단백질 생산방법 |
US20100040606A1 (en) | 2006-03-06 | 2010-02-18 | Symphogen A/S | Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections |
AU2007222991A1 (en) | 2006-03-09 | 2007-09-13 | The Board Of Regents Of The University Of Texas System | Compositions and methods based on peptide binding profiling |
MX2008011584A (es) | 2006-03-10 | 2008-12-12 | Warwick Effect Polymers Ltd | Polimeros. |
WO2007110755A1 (en) | 2006-03-27 | 2007-10-04 | Medical Therapies Limited | Prophylaxis or treatment of cardiovascular inflammation |
EP2014676B1 (en) | 2006-04-20 | 2012-03-07 | Kringle Pharma Inc. | Hgf precursor protein mutant and activated form thereof |
US20090253156A1 (en) | 2006-05-05 | 2009-10-08 | Perkinelmer Las, Inc. | Mass spectrometry methods for multiplexed quantification of protein kinases and phosphatases |
EP2348106B1 (en) | 2006-05-08 | 2014-07-02 | Adaerata, Limited Partnership | Chimeric proteins, cells comprising same, and assays using same |
EP2502628B1 (en) | 2006-06-23 | 2016-12-14 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptide sequences involved in cancer |
US20120128661A1 (en) | 2006-06-23 | 2012-05-24 | Alethia Biotherapeutics Inc. | Polynucleotide and polypeptide sequences involved in cancer |
EP2041556A1 (en) | 2006-06-28 | 2009-04-01 | RGB Technologies AB | A sensor kit and a system for detecting an analyte in a test environment |
US8198046B2 (en) | 2006-07-11 | 2012-06-12 | Danisco Us Inc. | KEX2 cleavage regions of recombinant fusion proteins |
US20080242607A1 (en) | 2006-07-21 | 2008-10-02 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
WO2008012362A2 (en) | 2006-07-27 | 2008-01-31 | Oxford Genome Sciences (Uk) Ltd | New protein isoforms and uses thereof |
WO2008016356A2 (en) | 2006-08-02 | 2008-02-07 | Genizon Biosciences | Genemap of the human genes associated with psoriasis |
AU2007284651B2 (en) | 2006-08-09 | 2014-03-20 | Institute For Systems Biology | Organ-specific proteins and methods of their use |
US8314221B2 (en) | 2006-09-07 | 2012-11-20 | Laurence Claude Faure | Pharmacodiagnostic test targeting oncology and neurodegeneration |
WO2008033932A2 (en) | 2006-09-13 | 2008-03-20 | The Institutes For Pharmaceutical Discovery, Llc | Biarylthiazole carboxylic acid derivatives as protein tyrosine phosphatase-ib inhibitors |
ES2394227T3 (es) | 2006-10-30 | 2013-01-23 | Sanrx Pharmaceuticals, Inc. | Dipterinilo cálcico pentahidratado (DCP) y utilizaciones terapéuticas del mismo |
DE102006051516A1 (de) | 2006-10-31 | 2008-05-08 | Curevac Gmbh | (Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins |
MX2009006277A (es) | 2006-12-14 | 2009-07-24 | Medarex Inc | Anticuerpos humanos que se enlazan a cd70 y usos de los mismos. |
EP2114948B1 (en) | 2006-12-28 | 2014-06-25 | AbbVie Inc. | Inhibitors of poly(adp-ribose)polymerase |
DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
WO2008086426A2 (en) | 2007-01-09 | 2008-07-17 | Cleveland Biolabs, Inc. | Methods for increasing and mobilizing hematopoietic stem cells |
WO2008104803A2 (en) | 2007-02-26 | 2008-09-04 | Oxford Genome Sciences (Uk) Limited | Proteins |
WO2008124483A1 (en) | 2007-04-04 | 2008-10-16 | Specigen, Inc. | Protein cage immunotherapeutics |
WO2009009186A2 (en) | 2007-04-13 | 2009-01-15 | The Regents Of The University Of California | Receptors useful for gas phase chemical sensing |
US20080306007A1 (en) | 2007-04-30 | 2008-12-11 | Newcastle Innovation Limited | Agents for prophylaxis or treatment of neurological related diseases and conditions |
EP2155177A2 (en) | 2007-04-30 | 2010-02-24 | Intezyne Technologies Incorporated | Modification of biological targeting groups for the treatment of cancer |
US8143372B2 (en) | 2007-05-21 | 2012-03-27 | Children's Hospital & Research Center Oakland | Synthetic regulators of ferritin protein nanocage pores and methods of use thereof |
US20100093554A1 (en) | 2007-06-01 | 2010-04-15 | Keting Chu | Methods for identifying biomarkers, autoantibody signatures, and stratifying subject groups using peptide arrays |
WO2009004329A1 (en) | 2007-07-02 | 2009-01-08 | Cancer Research Technology Limited | 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors |
US9018138B2 (en) | 2007-08-16 | 2015-04-28 | The Johns Hopkins University | Compositions and methods for generating and screening adenoviral libraries |
AU2008295248A1 (en) | 2007-09-07 | 2009-03-12 | Symphogen A/S | Methods for recombinant manufacturing of anti-RSV antibodies |
EP2197908A2 (en) | 2007-09-27 | 2010-06-23 | Dako Denmark A/S | Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics |
GB0719644D0 (en) | 2007-10-05 | 2007-11-14 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
EP2538223A3 (en) | 2007-11-05 | 2013-04-24 | Nordic Bioscience A/S | Biochemical markers for CVD risk assessment |
US20100298368A1 (en) | 2007-11-06 | 2010-11-25 | Amira Pharmaceuticals, Inc. | Antagonists of pgd2 receptors |
EP2071334A1 (en) | 2007-12-14 | 2009-06-17 | Transmedi SA | Compositions and methods of detecting TIABS |
WO2009111088A2 (en) | 2008-01-02 | 2009-09-11 | The Johns Hopkins University | Antitumor immunization by liposomal delivery of vaccine to the spleen |
US20090239229A1 (en) | 2008-03-14 | 2009-09-24 | Dnar, Inc | DNA Repair Proteins Associated With Triple Negative Breast Cancers and Methods of Use Thereof |
US8568709B2 (en) | 2008-03-20 | 2013-10-29 | University Health Network | Thymidylate kinase fusions and uses thereof |
WO2009134370A2 (en) | 2008-04-30 | 2009-11-05 | University Of Vermont And State Agricultural College | Methods and products relating to gsk3 beta regulation |
CA2723824C (en) | 2008-05-09 | 2022-12-06 | Surmodics Pharmaceuticals, Inc. | Biocompatible and biodegradable elastomeric polymers |
EP2306993B1 (en) | 2008-05-26 | 2014-03-12 | Universität Zürich | Protamine/rna nanoparticles for immunostimulation |
US8071807B2 (en) | 2008-07-03 | 2011-12-06 | Panmira Pharmaceuticals, Llc | Antagonists of prostaglandin D2 receptors |
US8148088B2 (en) | 2008-07-18 | 2012-04-03 | Abgent | Regulation of autophagy pathway phosphorylation and uses thereof |
EP2309853A4 (en) | 2008-08-01 | 2012-04-25 | Lixte Biotechnology Inc | METHOD FOR CELL MITITULATING BY INHIBITION OF SERIN / THREONINE PHOSPHATASE |
EP2328893B1 (en) | 2008-08-08 | 2013-03-20 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
US20110171312A1 (en) | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Modified therapeutic peptides, methods of their preparation and use |
WO2010033240A2 (en) | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Carbohydrate-based drug delivery polymers and conjugates thereof |
WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
KR20110084280A (ko) | 2008-11-03 | 2011-07-21 | 알레시아 바이오쎄라퓨틱스 인코포레이티드 | 종양 항원의 생물 활성을 특이적으로 차단하는 항체 |
CA2766747C (en) * | 2009-07-10 | 2019-04-02 | Innate Pharma | Tlr3 binding agents |
WO2011017687A1 (en) | 2009-08-06 | 2011-02-10 | Ray Partha S | Diagnosis of primary and metastatic basal-like breast cancer and other cancer types |
WO2011054112A1 (en) * | 2009-11-03 | 2011-05-12 | Alethia Biotherapeutics Inc. | Antibodies that specifically block the biological activity of kidney associated antigen 1 |
US8895001B2 (en) | 2010-03-11 | 2014-11-25 | Merrimack Pharmaceuticals, Inc. | Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers |
US20110233107A1 (en) | 2010-03-23 | 2011-09-29 | Emily Jainine Lockett | Personal Cosmetic Palette |
CA2829105C (en) * | 2011-03-31 | 2019-09-24 | Alethia Biotherapeutics Inc. | Antibodies against kidney associated antigen 1 and antigen binding fragments thereof |
PL2802351T3 (pl) * | 2012-01-09 | 2019-11-29 | Adc Therapeutics Sa | Środki do leczenia potrójnie negatywnego raka piersi |
-
2012
- 2012-03-28 CA CA2829105A patent/CA2829105C/en active Active
- 2012-03-28 RS RS20190975A patent/RS59080B1/sr unknown
- 2012-03-28 LT LTEP16190193.9T patent/LT3173427T/lt unknown
- 2012-03-28 HU HUE16190193A patent/HUE045943T2/hu unknown
- 2012-03-28 CA CA2888908A patent/CA2888908A1/en not_active Abandoned
- 2012-03-28 JP JP2014501372A patent/JP6294221B2/ja active Active
- 2012-03-28 PL PL16190193T patent/PL3173427T3/pl unknown
- 2012-03-28 CN CN201610534416.0A patent/CN106146664B/zh active Active
- 2012-03-28 AU AU2012234754A patent/AU2012234754B2/en active Active
- 2012-03-28 WO PCT/CA2012/000296 patent/WO2012129668A1/en active Application Filing
- 2012-03-28 DK DK16190193.9T patent/DK3173427T3/da active
- 2012-03-28 KR KR1020137026861A patent/KR101993259B1/ko active IP Right Grant
- 2012-03-28 ES ES16190193T patent/ES2743913T3/es active Active
- 2012-03-28 CN CN201280015597.6A patent/CN103492418B/zh active Active
- 2012-03-28 BR BR112013025198-0A patent/BR112013025198A2/pt not_active Application Discontinuation
- 2012-03-28 CA CA2893376A patent/CA2893376A1/en not_active Abandoned
- 2012-03-28 EP EP16190193.9A patent/EP3173427B1/en active Active
- 2012-03-28 ES ES12765926.6T patent/ES2615387T3/es active Active
- 2012-03-28 US US14/036,204 patent/US8937163B2/en active Active
- 2012-03-28 PT PT16190193T patent/PT3173427T/pt unknown
- 2012-03-28 SI SI201231645T patent/SI3173427T1/sl unknown
- 2012-03-28 EA EA201391423A patent/EA038979B1/ru unknown
- 2012-03-28 MX MX2013011354A patent/MX352373B/es active IP Right Grant
- 2012-03-28 EP EP19155812.1A patent/EP3511345A1/en not_active Withdrawn
- 2012-03-28 EP EP12765926.6A patent/EP2691421B1/en active Active
- 2012-03-28 DK DK12765926.6T patent/DK2691421T3/en active
- 2012-03-28 KR KR1020197017755A patent/KR102140984B1/ko active IP Right Grant
-
2013
- 2013-09-15 IL IL228434A patent/IL228434B/en active IP Right Grant
- 2013-09-18 ZA ZA2013/07027A patent/ZA201307027B/en unknown
-
2014
- 2014-12-02 US US14/558,186 patent/US9393302B2/en active Active
-
2016
- 2016-04-25 US US15/137,368 patent/US9828426B2/en active Active
-
2017
- 2017-11-13 US US15/811,545 patent/US10597450B2/en active Active
- 2017-12-07 JP JP2017235147A patent/JP6650432B2/ja active Active
-
2018
- 2018-04-24 IL IL258914A patent/IL258914A/en unknown
-
2019
- 2019-05-05 IL IL266452A patent/IL266452B/en active IP Right Grant
- 2019-09-03 HR HRP20191590 patent/HRP20191590T1/hr unknown
- 2019-09-16 CY CY20191100961T patent/CY1122156T1/el unknown
- 2019-12-09 US US16/707,482 patent/US20210054067A1/en not_active Abandoned
-
2020
- 2020-01-17 JP JP2020005907A patent/JP2020074785A/ja not_active Ceased
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1122156T1 (el) | Αντισωματα κατα του σχετιζομενου με τον νεφρο αντιγονου 1 και αντιγονοδεσμευτικα θραυσματα αυτων | |
CY1123883T1 (el) | Ανθρωποποιημενα αντισωματα κατα της liv-1 και χρηση αυτων για τη θεραπευτικη αντιμετωπιση του καρκινου | |
CY1124437T1 (el) | Ανθρωπινα αντισωματα κατα toy pd-l1 | |
CY1126115T1 (el) | Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων | |
CY1122091T1 (el) | Μορια δεσμευσης-cd37 και ανοσοσυζευγματα εξ αυτων | |
CY1119799T1 (el) | Συνδυασμος αντισωματων anti-kir και αντισωματων anti-pd-1 για αγωγη καρκινου | |
CY1119794T1 (el) | Ενωσεις αναστολεων ε-σελεκτινης | |
CY1120913T1 (el) | Μονοκλωνικα αντισωματα εναντι προγαστρινης και η χρηση τους | |
MX2016014189A (es) | Anticuerpos anti ligando 1 de muerte programada (b7-h1) y anti antigeno 4 de linfocito t citotoxico (anti-ctla-4) para tratar el cancer de pulmon no microcitico. | |
CY1121538T1 (el) | Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi) | |
EA201791050A1 (ru) | Конъюгаты антител и лекарственных средств | |
MX360141B (es) | Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer. | |
EA201492137A1 (ru) | Антитела к cd33 и их применение в лечении рака | |
EA201390472A1 (ru) | Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты | |
EA201791393A2 (ru) | АНТИТЕЛА К ErbB3 И ИХ ПРИМЕНЕНИЕ | |
CY1120123T1 (el) | Μονοκλωνικα αντισωματα κατα της gt468 για τη θεραπεια του καρκινου | |
MX2016002051A (es) | Metodos y kits para la subtipificacion molecular de tumores. | |
CY1124006T1 (el) | Συζευγμενα αντισωματα κατα toy ly75 για τη θεραπεια του καρκινου | |
EA201300470A1 (ru) | Антитела | |
CY1120063T1 (el) | Αντισωματα κατα του ανθρωπινου dlk-1 που εχει δραση κατα των ογκων in vivo | |
CY1119430T1 (el) | Anti-s100a7 αντισωματα για τη θεραπευτικη αγωγη και διαγνωση καρκινου | |
EA201501095A1 (ru) | Эффективное лечение нмрл и прогностический клинический маркер чувствительной к лечению опухоли | |
TR201905240T4 (tr) | LIV-1'e hümanize edilmiş antikorlar ve bunların kanserin tedavisinde kullanımı. | |
EA202092450A2 (ru) | Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей |